Douglas Murphy-Chutorian Sells 1,250 Shares of Semler Scientific, Inc. (OTCMKTS:SMLR) Stock

Semler Scientific, Inc. (OTCMKTS:SMLR) CEO Douglas Murphy-Chutorian sold 1,250 shares of the stock in a transaction that occurred on Monday, October 11th. The shares were sold at an average price of $129.01, for a total value of $161,262.50. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.

Douglas Murphy-Chutorian also recently made the following trade(s):

  • On Monday, October 4th, Douglas Murphy-Chutorian sold 1,250 shares of Semler Scientific stock. The shares were sold at an average price of $127.28, for a total value of $159,100.00.

OTCMKTS:SMLR traded up $3.65 during trading hours on Wednesday, hitting $136.65. The company’s stock had a trading volume of 83,744 shares, compared to its average volume of 15,260. The business’s 50-day moving average is $114.62 and its two-hundred day moving average is $112.95. The company has a market capitalization of $922.93 million, a PE ratio of 50.61, a PEG ratio of 1.52 and a beta of 0.85. Semler Scientific, Inc. has a 52-week low of $52.90 and a 52-week high of $144.87.

Semler Scientific (OTCMKTS:SMLR) last released its quarterly earnings data on Sunday, August 1st. The medical equipment provider reported $0.83 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.61 by $0.22. The firm had revenue of $14.31 million during the quarter, compared to analysts’ expectations of $14.53 million. Semler Scientific had a return on equity of 68.78% and a net margin of 43.39%. On average, research analysts anticipate that Semler Scientific, Inc. will post 2.82 EPS for the current fiscal year.

SMLR has been the subject of several recent research reports. Lake Street Capital increased their price target on Semler Scientific from $150.00 to $200.00 and gave the stock a “buy” rating in a report on Tuesday, September 28th. B. Riley reaffirmed a “buy” rating and set a $151.00 price target on shares of Semler Scientific in a report on Wednesday, August 4th. Colliers Securities reaffirmed an “average” rating and set a $151.00 price target on shares of Semler Scientific in a report on Tuesday, September 28th. TheStreet raised Semler Scientific from a “d-” rating to an “a-” rating in a report on Tuesday, September 28th. Finally, Zacks Investment Research downgraded Semler Scientific from a “buy” rating to a “hold” rating in a report on Thursday, October 7th. Two research analysts have rated the stock with a hold rating and two have given a buy rating to the stock. Based on data from MarketBeat.com, Semler Scientific currently has an average rating of “Buy” and a consensus price target of $157.75.

About Semler Scientific

Semler Scientific, Inc engages in the provision of technology and software solutions to improve the clinical effectiveness of healthcare providers. Its multi-test service platform, WellChec, comprehensively evaluate its customers patients for chronic disease, including heart attacks and strokes, using its QuantaFlo product as well as other tests.

Featured Story: Strangles

Insider Buying and Selling by Quarter for Semler Scientific (OTCMKTS:SMLR)

Receive News & Ratings for Semler Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Semler Scientific and related companies with MarketBeat.com's FREE daily email newsletter.